Logo
LUMIFIL L Max with Lidocaine 1 x 1ml

LUMIFIL L Max with Lidocaine 1 x 1ml

LUMIFIL

Dermal filler
  • Class III CE Marked hyaluronic acid dermal filler within the EU/EEA, as part of the LUMIFIL with Lidocaine range.
  • Manufactured under an ISO 13485 Compliant quality management system by BNC Korea, with BDDE purification processes to achieve low Residual cross Linker and high product purity.
  • Marketed as an ultra High purity HA filler and described by the brand as meeting stringent safety standards, including successful clinical evaluation against a leading reference HA filler.
  • Distributed only to professional users (licensed healthcare or aesthetic practitioners), in line with medical device regulations and local professional standards; packaging and labelling include CE mark, device classification, lot/expiry and IFU as required.
High-density hyaluronic acid filler for deep facial augmentation and contouring

Description

LUMIFIL L-Max with Lidocaine (1 x 1ml) is a premium, high-density cross-linked hyaluronic acid dermal filler designed for deep tissue augmentation, structural contouring and treatment of pronounced wrinkles. It is the thickest and most robust formulation in the LUMIFIL range, engineered for subcutaneous and deep-dermal areas such as the nose, cheeks, jawline and chin, as well as for deep folds including nasolabial and marionette lines. Developed using non-animal HA and advanced cross-linking with patented particle technology, L-Max combines high viscoelasticity, low phase angle and a very high molecular weight HA matrix (approx. 2,500,000 Da) to provide powerful lift, strong volumising effect and long-lasting projection with minimal migration. The addition of 0.3% lidocaine improves patient comfort during injection, making it suitable for demanding facial sculpting procedures where both precision and longevity are required.

Bnefits

  • Thickest and most robust gel in the LUMIFIL portfolio, ideal for deep structural facial augmentation and subcutaneous contouring.
  • High-density, high-viscoelasticity formulation provides strong lift, projection and long-lasting volume in areas such as nose, cheeks, jawline and chin.
  • Low phase angle rheology helps the product stay closer to the injection site, reducing undesirable migration and supporting precise sculpting.
  • Patented particle technology ensures uniform HA particle structure for smooth extrusion, controlled moulding and consistent treatment outcomes.
  • High molecular weight HA (approx. 2,500,000 Da) delivers one of the densest HA fillers in its class, supporting extended duration of effect.
  • Includes 0.3% lidocaine for improved patient comfort and reduced pain during injection.
  • Suitable for deep wrinkles and folds (e.g. nasolabial folds, marionette lines) where a more substantial, supportive filler is required.
  • Ultra-high purity HA with low residual BDDE, aligning with current expectations for safety and quality in medical HA fillers.
  • CE-marked and used widely by aesthetic practitioners for non-surgical rhinoplasty, jawline reshaping and chin augmentation.
  • Designed to integrate smoothly with surrounding tissues while maintaining structural integrity and a natural contour.

Indications

  • Deep facial augmentation and contouring of subcutaneous (Sub-Q) areas.
  • Non-surgical nose reshaping/rhinoplasty.
  • Cheek enhancement and mid-face volume restoration.
  • Jawline contouring and definition.
  • Chin augmentation and projection.
  • Treatment of deep and pronounced wrinkles and folds, including nasolabial folds and marionette lines.
  • Restoration of structural volume in areas of significant soft tissue or age-related volume loss, where a thick, robust filler is clinically appropriate.

Composition

  • Cross-linked hyaluronic acid (HA) 20 mg/ml (non-animal sourced, obtained via bacterial fermentation).
  • Lidocaine hydrochloride 0.3% (3 mg/ml) as a local anaesthetic for reduced injection discomfort.
  • Physiological phosphate-buffered saline and sterile excipients as detailed in the official Instructions for Use (IFU).
  • High molecular weight HA base (approx. 2,500,000 Da prior to cross-linking) processed to create a dense, high-viscosity gel.

Formulation

  • Monophasic, high-density cross-linked hyaluronic acid gel with lidocaine.
  • Advanced cross-linking and patented particle technology producing a uniform 3D HA matrix with high viscoelasticity and cohesivity.
  • Designed specifically for deep dermal to subcutaneous injection, providing significant lift and projection.
  • Zero- or ultra-low-BDDE residue profile according to LUMIFIL brand communications, aligning with modern safety expectations for HA fillers.

Packaging

  • Standard presentation: 1 x 1 ml pre-filled sterile syringe of LUMIFIL L-Max with Lidocaine per box.
  • Clinic/wholesale options may include outer cartons containing 10 x 1 ml boxes, each with an individual syringe.
  • Each pack typically includes sterile disposable needles (commonly 25–27G, exact gauge to be confirmed on pack) and an IFU leaflet.
  • Outer carton and blister are labelled with CE mark, lot/batch number, expiry date, storage conditions and manufacturer details.

Usage

  • For professional use only and must be administered by suitably trained healthcare or aesthetic practitioners experienced in dermal filler injections.
  • Intended injection depth is mid-dermis to deep dermis and subcutaneous tissue depending on the indication and area (e.g. jawline, chin, nose, cheeks, deep folds).
  • Use appropriate injection techniques such as small bolus injections, linear threading, fanning or depot placement in deep planes, avoiding intravascular injection at all times.
  • Prior to treatment, perform a full medical history, examination and informed consent process, assessing suitability and discussing risks, benefits and alternatives.
  • Prepare the skin by cleansing and disinfecting the treatment area; use sterile gloves and equipment and maintain strict aseptic technique.
  • Inject slowly with controlled pressure, aspirating in accordance with clinic protocol where appropriate, particularly in high-risk vascular areas (e.g. nose, nasolabial region).
  • After injection, gently mould and contour the filler if required to achieve a smooth, even profile; avoid excessive manipulation that could displace the product.
  • Provide patients with detailed aftercare instructions, typically including advice to avoid makeup, alcohol, strenuous exercise, and extremes of temperature (sauna/steam rooms, sunbeds) for at least 24 hours or as per clinic policy.
  • Schedule follow-up assessments as needed to evaluate results, manage any side effects and determine if touch-ups are indicated.
  • Always consult and follow the official LUMIFIL technical brochure and IFU for precise guidance on indications, injection depths, contraindications, precautions and management of complications.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, lidocaine or other amide-type local anaesthetics, or any of the excipients.
  • Presence of active skin infection, inflammation or disease at or near the intended injection site (e.g. acne flare, dermatitis, herpes simplex/cold sores).
  • History of severe anaphylactic reactions or multiple severe allergies that make elective injectable treatments high risk.
  • Bleeding disorders, use of certain anticoagulant or antiplatelet therapies, or other haematological conditions where injection could pose additional risk, unless carefully evaluated by a qualified clinician.
  • Autoimmune diseases, uncontrolled systemic illness or immunosuppressed states where dermal filler use may be contraindicated, unless risk–benefit has been carefully assessed.
  • Pregnancy and breastfeeding, as elective cosmetic filler procedures are generally avoided in these groups due to insufficient safety data.
  • Previous permanent fillers or foreign-body implants in the planned treatment area where potential product interaction or tissue compromise is a concern, unless deemed safe by an experienced practitioner.
  • Any further contraindications and specific patient exclusions described in the official IFU and local clinical guidelines should be strictly observed.

Adverse Effects

  • Common transient injection-site reactions including redness, swelling, tenderness, pain, bruising, itching or small haematoma.
  • Temporary lumps, nodules, asymmetry or surface irregularities, especially if injection depth or placement is suboptimal, or if product is not adequately moulded.
  • Potential for delayed-onset nodules or inflammatory reactions, including localised granulomatous responses, as with other HA fillers.
  • Risk of infection, abscess formation or cellulitis if aseptic technique is not strictly followed or if post-care instructions are not adhered to.
  • Rare hypersensitivity or allergic reactions to hyaluronic acid or lidocaine, which may present with swelling, erythema, pruritus or systemic symptoms.
  • Serious but rare complications associated with all injectable HA fillers, including intravascular injection with vascular occlusion, tissue ischaemia or necrosis, and very rare risks of visual disturbance or blindness if filler enters vessels supplying the ocular region.
  • Practitioners must be trained in early recognition and management of complications, including the use of hyaluronidase, massage, warm compresses and emergency pathways, and patients should be counselled to seek urgent medical attention if they develop severe pain, blanching, dusky or mottled skin, visual symptoms, progressive swelling or signs of infection.
  • All suspected serious adverse events should be documented and reported according to local pharmacovigilance and device vigilance requirements.

Storage Conditions

  • Store LUMIFIL L-Max in its original packaging at a controlled room temperature, typically between 2°C and 25–30°C, as specified on the outer carton and IFU.
  • Protect from direct sunlight and do not freeze; avoid extreme heat or cold that could compromise product integrity.
  • Keep out of reach of children and unauthorised persons; store in a secure clinical environment with restricted access.
  • Do not use if the blister or syringe is damaged, if the gel appears discoloured or contains visible particulates, or if the expiry date has passed.
  • Follow any additional storage and handling instructions provided by the manufacturer, including guidance on transport conditions and shelf life.

Duration

Most distributor and brand communications report that LUMIFIL L-Max provides effective results for approximately 9\u201315 months, depending on injection site, volume used, patient metabolism, lifestyle and practitioner technique. Some sources quote a more typical window of 9\u201312 months, with maintenance or repeat treatments performed at the clinician\u2019s discretion when volume or contour begins to diminish.

Onset

Structural augmentation and contouring effects are visible immediately after injection, as with other HA fillers. Final, settled results are usually observed after initial post-procedure swelling and erythema resolve, typically within several days to about two weeks.

Browse more Dermal filler

Top Treatments

Top Cities in the UK